https://bayespharma.onrender.com/blog AI-driven drug discovery, pipeline realities, and the Bayesian statistical infrastructure behind both. en-us https://bayespharma.onrender.com/blog/dose-is-part-of-the-drug-molecule-first-discovery-stops-too-early https://bayespharma.onrender.com/blog/dose-is-part-of-the-drug-molecule-first-discovery-stops-too-early Sat, 11 Jul 2026 10:00:00 GMT A chemical structure does not treat a patient. A regimen creates a time-varying exposure in a particular tissue, in a particular biological state. Discovery becomes more predictive when dose, schedule, target engagement, and patient context are treated as design variables from the beginning. Bayes Pharma Team Drug Discovery Pharmacometrics Translational Science https://bayespharma.onrender.com/blog/human-genetics-is-natures-clinical-trial-not-a-free-pass https://bayespharma.onrender.com/blog/human-genetics-is-natures-clinical-trial-not-a-free-pass Sat, 11 Jul 2026 09:50:00 GMT Genetic evidence can sharply improve confidence that a target matters in human disease. It can also mislead when lifelong variation is treated as equivalent to short-term pharmacology, direction of effect is unclear, or pleiotropy and population context are ignored. Bayes Pharma Team Drug Discovery Human Genetics Target Validation https://bayespharma.onrender.com/blog/protein-is-not-a-statue-conformational-ensembles-drug-discovery https://bayespharma.onrender.com/blog/protein-is-not-a-statue-conformational-ensembles-drug-discovery Sat, 11 Jul 2026 09:40:00 GMT Anfinsen taught us that sequence encodes a protein's accessible structure. Modern biophysics adds the crucial detail: proteins occupy shifting energy landscapes, and medicines often work by selecting, stabilizing, or excluding particular states. Bayes Pharma Team Structural Biology Drug Discovery Technical Deep Dive https://bayespharma.onrender.com/blog/selectivity-is-not-precision-designed-polypharmacology https://bayespharma.onrender.com/blog/selectivity-is-not-precision-designed-polypharmacology Sat, 11 Jul 2026 09:30:00 GMT Promiscuous chemistry is dangerous, but perfect single-target selectivity is not automatically superior. Complex diseases are network failures, and some medicines succeed because they engage a deliberate pattern of targets within a tolerable exposure window. Bayes Pharma Team Drug Discovery Systems Pharmacology Medicinal Chemistry https://bayespharma.onrender.com/blog/build-a-failure-atlas-negative-data-drug-discovery https://bayespharma.onrender.com/blog/build-a-failure-atlas-negative-data-drug-discovery Sat, 11 Jul 2026 09:20:00 GMT A failed assay, irreproducible phenotype, toxic series, or negative trial is not empty space. Properly structured, it tells us which causal link broke -- target, exposure, engagement, biology, safety, or patient selection -- and prevents the same mistake from being rediscovered. Bayes Pharma Team Drug Discovery Evidence Engineering R&D Productivity https://bayespharma.onrender.com/blog/from-code-to-bio-why-ai-labs-are-racing-into-drug-discovery https://bayespharma.onrender.com/blog/from-code-to-bio-why-ai-labs-are-racing-into-drug-discovery Sat, 11 Jul 2026 09:00:00 GMT DeepMind, Nvidia, Meta, Microsoft, and a wave of AI-native biotechs are pointing the same scaling-law playbook that built large language models at the much harder problem of biology -- and the people running these labs are now saying the drug discovery timeline itself is the target. Bayes Pharma Team AI & Biology Industry Trends https://bayespharma.onrender.com/blog/negative-data-moat-failed-experiments-drug-discovery https://bayespharma.onrender.com/blog/negative-data-moat-failed-experiments-drug-discovery Sat, 11 Jul 2026 04:00:00 GMT Published science is optimized to show what worked. Drug discovery needs the opposite too: inactive compounds, failed syntheses, contradictory assays, abandoned targets, and the exact context that explains why. In an AI-driven era, that “negative” evidence may become the most defensible competitive advantage a discovery company can own. Bayes Pharma Team Drug Discovery AI & Biology Research Quality https://bayespharma.onrender.com/blog/target-validation-causal-inference-not-correlation https://bayespharma.onrender.com/blog/target-validation-causal-inference-not-correlation Fri, 10 Jul 2026 04:00:00 GMT A gene can be elevated in disease, correlated with severity, and beautifully connected in a knowledge graph -- yet still be the wrong therapeutic target. The next generation of target validation will treat genetics, perturbation, tissue context, temporal order, and rescue experiments as a causal argument rather than a collection of associations. Bayes Pharma Team Target Validation Genomics AI & Biology https://bayespharma.onrender.com/blog/bayesian-methods-quiet-infrastructure-ai-drug-discovery https://bayespharma.onrender.com/blog/bayesian-methods-quiet-infrastructure-ai-drug-discovery Thu, 09 Jul 2026 09:00:00 GMT The headlines belong to generative chemistry and structure prediction. The layer deciding what to trust, when to stop a trial, and how confident to be in a dose -- the layer that turns a faster pipeline into a defensible one -- is Bayesian statistics, and it rarely gets named. Bayes Pharma Team Bayesian Statistics Pharmacometrics https://bayespharma.onrender.com/blog/next-best-experiment-active-learning-drug-discovery https://bayespharma.onrender.com/blog/next-best-experiment-active-learning-drug-discovery Wed, 08 Jul 2026 04:00:00 GMT Early discovery teams often ask which molecule is predicted to be most potent. A better question is which experiment will reduce the most consequential uncertainty. Active learning, Bayesian optimization, and multi-objective design turn discovery from a leaderboard of scores into a strategy for learning. Bayes Pharma Team Bayesian Statistics Drug Discovery Technical Deep Dive https://bayespharma.onrender.com/blog/compute-to-clinic-gap-what-ai-actually-speeds-up https://bayespharma.onrender.com/blog/compute-to-clinic-gap-what-ai-actually-speeds-up Tue, 07 Jul 2026 09:00:00 GMT Generative chemistry and structure prediction have genuinely compressed the front half of drug discovery. Clinical development, statistical power, and regulatory review still run on a clock that GPUs can't turn faster -- and understanding exactly where the line falls is the difference between real progress and hype. Bayes Pharma Team Drug Development Regulatory https://bayespharma.onrender.com/blog/molecule-is-not-the-medicine-developability-day-one https://bayespharma.onrender.com/blog/molecule-is-not-the-medicine-developability-day-one Mon, 06 Jul 2026 04:00:00 GMT A potent structure in a slide deck is not a therapy. The medicine is the molecule plus its solid form, formulation, exposure, regimen, manufacturing process, and patient context. Programs that postpone developability do not remove these constraints; they merely discover them later, when failure is more expensive. Bayes Pharma Team Drug Development Pharmaceutics Preclinical https://bayespharma.onrender.com/blog/foundation-models-for-biology-field-guide https://bayespharma.onrender.com/blog/foundation-models-for-biology-field-guide Sat, 27 Jun 2026 09:00:00 GMT Transformer, tokenizer, and RLHF became common vocabulary for language models almost overnight. Biology now has its own emerging vocabulary -- AlphaFold, ESM, RFdiffusion, diffusion-based molecular generators -- and understanding how they compose into a pipeline is the fastest way to understand where this field is actually headed. Bayes Pharma Team AI & Biology Technical Deep Dive